Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Drug Resistance, Neoplasm
  • Genes, erbB-1
  • Lung Neoplasms

abstract

  • The majority of patients with advanced lung adenocarcinomas harboring EGFR exon20ins do not respond to EGFR TKI therapy. Standard chemotherapy should be used as first-line therapy. These patients have an OS similar to that of patients with sensitizing EGFR mutations. Individuals with certain variants such as FQEA and ASV may respond to erlotinib. Cancer 2015;121:3212-3220. © 2015 American Cancer Society.

publication date

  • January 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4807634

Digital Object Identifier (DOI)

  • 10.1002/cncr.29493

PubMed ID

  • 26096453

Additional Document Info

start page

  • 3212

end page

  • 20

volume

  • 121

number

  • 18